TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18543329
Drug: Tetracycline (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline (500 mg orally twice a day for 28 days)
Study: 15910187
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) + Pulsed Dye Laser (PDL)
Study: 1872042
Drug: Felbinac Gel
Normalized name: felbinac
DrugBank: Felbinac (DB07477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felbinac Gel 3% (1 g, three times daily)
Study: 29103065
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise intervention (2 weekly sessions for 12 months)
Study: 25800784
Drug: TDF monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF monotherapy (300 mg/day)
Study: 25800784
Drug: TDF and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF and ETV combination therapy (TDF 300 mg/day and ETV 1 mg/day)
Study: 24827808
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m² on days 21, 28, 35, 42, 175, 182, 189, and 196)
Study: 22751980
Drug: Combined anticoagulant-aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined anticoagulant-aspirin therapy (100-mg prophylactic dose)
Study: 22751980
Drug: Aspirin therapy
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin therapy (100-mg prophylactic dose)
Study: 18309485
Drug: S-1 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 treatment
Study: 17035614
Drug: 30 mEq
Normalized name: Rum-K, 30 mEq/15 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mEq of oral potassium citrate (Kcitrate)
Study: 17035614
Drug: Both K
Normalized name: Effer-K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both K supplements
Study: 11085844
Drug: Sexual dysfunction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sexual dysfunction treatments
Study: 10945508
Drug: Cefaclor 250
Normalized name: cefaclor 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 250 mg TID
Study: 18716314
Drug: Generic enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic enoxaparin (40 mg, single-dose subcutaneous administration)
Study: 10550150
Drug: Gemcitabine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1,000 mg/m² on days 1, 8, and 15 plus cisplatin 100 mg/m² on day 2, every 28 days
Study: 10550150
Drug: Mitomycin 6
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin 6 mg/m², ifosfamide 3,000 mg/m², and mesna on day 1 plus cisplatin 100 mg/m² on day 2, every 28 days
Study: 378732
Drug: Butorphanol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol (1 mg and 2 mg)
Study: 378732
Drug: Meperidine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (40 mg and 80 mg)
Study: 30556911
Drug: 2% tofacitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% tofacitinib ointment applied twice daily for 4 weeks
Study: 26605849
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy with subretinal delivery of a recombinant adeno‐associated viral vector carrying RPE65
Study: 19547808
Drug: Clozapine (n=115,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (n=115, 75-600 mg)
Study: 19547808
Drug: Haloperidol (n=105,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (n=105, dose range 2-15 mg)
Study: 19547808
Drug: Chlorpromazine (n=105,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (n=105, 100-400 mg)
Study: 8879890
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg PO QD, titrated to 50 mg losartan/12.5 mg HCTZ PO QD after 4 weeks, then to 50 mg losartan/25 mg HCTZ PO QD after 8 weeks)
Study: 8879890
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 mg PO QD, titrated to 10 mg PO QD after 4 weeks, then to 10 mg plus 25 mg HCTZ PO QD after 8 weeks)
Study: 6465669
Drug: Inhaled vasoactive
Normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled vasoactive intestinal peptide (VIP) 100 micrograms
Study: 6465669
Drug: Control solution
Normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control solution (1% human serum albumin in 2 ml 0.9% saline)
Study: 26875905
Drug: Shock wave
Normalized name: ELECTRODE GEL,H-WAVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shock wave therapy (SW group)
Study: 24824095
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment (nonweight bearing and early range of motion exercise)
Study: 20716300
Drug: Treatment addressing
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment addressing anxiety symptoms
Study: 16294506
Drug: New nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: New nevirapine tablet formulation (test, T)
Study: 16294506
Drug: Reference nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reference nevirapine tablet formulation (R)
Study: 11923816
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (bemiparin sodium 3500 IU/daily subcutaneously)
Study: 7577777
Drug: 0.5% plain
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% plain bupivacaine followed by a continuous infusion of 7 mL/h 0.25% bupivacaine
Study: 2122869
Drug: Amiodarone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (200 mg/day after impregnation)
Study: 2122869
Drug: Placebo phase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo phase (2 weeks) followed by 6 weeks of active treatment
Study: 31791239
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine at 1 μg·kg‐1
Study: 31791239
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline at 0.01 ml·kg‐1
Study: 28932090
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (400 mg) HL tablet
Study: 28932090
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (133.4 mg) HL tablet
Study: 15285274
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Codonopsis pilosula (CPG) and Gingko biloba (GB)
Study: 11583941
Drug: Sirolimus at
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus at 2 mg/d
Study: 11583941
Drug: Sirolimus at
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus at 5 mg/d
Study: 11583941
Drug: Sirolimus (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (both doses)
Study: 786045
Drug: THC (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (20 mg) in fast condition
Study: 786045
Drug: THC (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (20 mg) in slow condition
Study: 786045
Drug: Alcohol (intoxicating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (intoxicating doses)
Study: 25746966
Drug: Inhaled corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid (budesonide)
Study: 21627766
Drug: Gabapentin enacarbil
Normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin enacarbil (GEn) 1,200 mg (624 mg-equivalents gabapentin), twice daily for 14 days
Study: 21627766
Drug: Gabapentin capsules
Normalized name: Gabapentin Capsules
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin capsules
Study: 22157410
Drug: Non-CABG (percutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-CABG (percutaneous coronary intervention plus medical treatment)
Study: 16507375
Drug: CSDVC (clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSDVC (clindamycin phosphate 2% single-dose vaginal cream)
Study: 16507375
Drug: CVC (7-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVC (7-day regimen of clindamycin phosphate 2% vaginal cream)
Study: 12869610
Drug: Melatonin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (3 mg tablet)
Study: 10219129
Drug: Brånemark, IMZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brånemark, IMZ or Frialit‐2 endosseous implants with autogenous bone grafts
Study: 10219129
Drug: Oral implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral implants in periodontally healthy patients
Study: 25456960
Drug: Control (Standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Standard postoperative analgesic treatment with acetaminophen)
Study: 23364039
Drug: Recreational combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recreational combination gymnastics program (conducted twice a week for 12 weeks)
Study: 20425851
Drug: Tobramycin solution
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin solution for inhalation (TSI), 5 ml nebulized treatment twice a day for 28 days (one cycle), followed by 28 days off, for three cycles.
Study: 15739091
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml saline (group 1, n=18)
Study: 8590488
Drug: Ketamine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (2 mg.kg‐1)
Study: 8590488
Drug: Midazolam (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.3 mg.kg‐1)
Study: 1967418
Drug: Low-dose bradykinin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose bradykinin infusion (30 ng/kg per min)
Study: 1967418
Drug: Chronic bradykinin
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic bradykinin administration (6 days)
Study: 279137
Drug: 0.5% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% sodium fluoride solution (weekly mouth-rinsings)
Study: 31931509
Drug: Nicotine (2-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (2-mg lozenge)
Study: 25889057
Drug: Cognitive tests
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive tests administered in a familiar environment (Familiar cohort)
Study: 25889057
Drug: Cognitive tests
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive tests administered in a foreign environment (Foreign cohort)
Study: 22007904
Drug: Adapalene gel
Normalized name: Adapalene Gel
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adapalene gel and nadifloxacin cream
Study: 17668527
Drug: Adapalene gel
Normalized name: Adapalene Gel
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adapalene gel monotherapy
Study: 19797187
Drug: Telmisartan (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (80 mg/d)
Study: 16825271
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium 15 mmol twice daily (n = 28)
Study: 9862830
Drug: GLP-1 infusion
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 infusion (0, 0.375, 0.75, and 1.5 pmol/kg/min)
Study: 9862830
Drug: GLP-1 infusion
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 infusion (highest dose)
Study: 8549029
Drug: Atovaquone (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atovaquone (750 mg every 12 hours)
Study: 1834003
Drug: Warfarin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin and Aspirin
Study: 6800440
Drug: Preseasonal hyposensitisation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preseasonal hyposensitisation treatment with an aqueous rye extract
Study: 26697176
Drug: Ranolazine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine (500 mg, uptitrated to 1,000 mg at week 4)
Study: 23452432
Drug: Prediction model
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prediction model for OTC-medication use based on maternal characteristics
Study: 19479489
Drug: Estradiol 0.014
Normalized name: ESTRADIOL 0.014MG/DAY (MENOSTAR) PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol 0.014 mg/day
Study: 9759389
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (0.02 mg/ml, three times daily for 5 days)
Study: 9759389
Drug: Thio-tepa (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thio-tepa (four times daily for 6 weeks)
Study: 9759389
Drug: Distilled water
Normalized name: Distilled Water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distilled water (three times daily for 5 days)
Study: 26171392
Drug: Intra-articular bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular bupivacaine combined with intravenous parecoxib
Study: 26171392
Drug: Intravenous parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Intravenous parecoxib monotherapy (control group)
Study: 23919274
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg twice daily) and UDCA (1000-2000 mg daily, 20-30 mg/kg/day)
Study: 2138925
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic treatment (Control)
Study: 18375998
Drug: Abciximab infusion
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab infusion
Study: 27327862
Drug: High-dose bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose bolus tirofiban
Study: 12113544
Drug: Gabexate mesilate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabexate mesilate (GM), 2.0 mg/kg/hr, administered intravenously starting 24 hours before surgery until postoperative day 3 (preop GM group)
Study: 12113544
Drug: Gabexate mesilate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabexate mesilate (GM), administered at the beginning of surgery (intraop GM group)
Study: 2368745
Drug: Drug-use review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-use review (DUR) program intervention
Study: 29653652
Drug: Betrixaban (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betrixaban (80 mg)
Study: 22464802
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet + supplement
Study: 17901014
Drug: Occupation-focused, client-centered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupation-focused, client-centered occupational therapy
Study: 2087329
Drug: Needle acupuncture
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle acupuncture (stainless steel needles at point Hegu (L.I.4) on both sides)
Study: 2087329
Drug: Laser acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser acupuncture (helium-neon laser at points Hegu (L.I.4) and Jianqian (Extra.) on both sides for 1 min)
Study: 390674
Drug: Tiaprofenic acid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiaprofenic acid, 200 mg three times a day
Study: 390674
Drug: Ibuprofen, 400
Normalized name: Ibuprofen, 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen, 400 mg three times a day
Study: 31568698
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein isolate (WPI) supplementation (20 g/d) for 3 months
Study: 24389453
Drug: Sacha inchi
Normalized name: Abies sachalinensis var. sachalinensis oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacha inchi oil (10 or 15ml daily)
Study: 24389453
Drug: Sunflower oil
Normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower oil (10 or 15ml daily)
Study: 22968159
Drug: Nebulized hypertonic
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized hypertonic saline solution alone
Study: 19560158
Drug: Thimerosal-containing vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thimerosal-containing vaccines
Study: 15850499
Drug: Isradipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (30 mg SR at bedtime, plus 15 mg IR administered 2 h before methamphetamine infusion)
Study: 8735556
Drug: Vi capsular
Normalized name: typhoid vaccine VI capsular polysaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi capsular polysaccharide vaccine
Study: 9987143
Drug: Meningococcal A
Normalized name: MENINGOCOCCAL A/B/C/W/Y (PENBRAYA) KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal A + C control vaccine
Study: 1692602
Drug: Intranasal interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal interferon
Study: 19535229
Drug: Sublingual orally
Normalized name: Sublingual Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual orally disintegrating olanzapine (ODO)
Study: 17280773
Drug: Desmopressin (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin (0.1, 0.2, or 0.4 mg)
Study: 15088136
Drug: Home infusions
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home infusions
Study: 11427834
Drug: Propofol PCS
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol PCS (0.3 mg/kg bolus, zero lockout)
Study: 11427834
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam (0.05 mg/kg bolus, 1 mg increments as required)
Study: 3145014
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g cephradine
Study: 3145014
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g mezlocillin
Study: 3145014
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g cephradine
Study: 19362286
Drug: Stapled transanal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stapled transanal rectal resection alone or associated with transobturator tape, vaginal repair of the enterocele, or vaginal hysterectomy
Study: 19362286
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rectal and urogynecologic surgery with vaginal hysterectomy
Study: 8701892
Drug: Bolus recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus recombinant urokinase (rUK) administered as three bolus infusions of 1 million U over a 24-hour period
Study: 8370856
Drug: Nondirective (ND)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nondirective (ND) therapy
Study: 29432644
Drug: BF-200 ALA
Normalized name: ALA
DrugBank: alpha-Linolenic acid (DB00132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BF-200 ALA (5-aminolaevulinic acid gel)
Study: 29432644
Drug: MAL (methyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAL (methyl aminolaevulinate cream)
Study: 19468050
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (general)
Study: 12826700
Drug: recombinant follicle-stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant follicle-stimulating hormone (recFSH) 2 x 225 IU per week + hCG
Study: 12826700
Drug: recombinant follicle-stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant follicle-stimulating hormone (recFSH) 3 x 150 IU per week + hCG
Study: 12826700
Drug: hCG alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG alone (pre-treatment)
Study: 12826700
Drug: Combined gonadotropin
Normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined gonadotropin treatment
Study: 7793186
Drug: Plain 0.15%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain 0.15% bupivacaine (150 mg.100 ml‐1)
Study: 7793186
Drug: Bupivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine with adrenaline (1.5 micrograms ml‐1)
Study: 1828183
Drug: LHRH analogue
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH analogue Zoladex (administered subcutaneously every 28 days)
Study: 6758745
Drug: Aspirin (1950
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (1950 mg/day orally)
Study: 6758745
Drug: Indomethacin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (75 mg/day orally)
Study: 16710890
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (Group B)
Study: 9089426
Drug: Selegiline transdermal
Normalized name: Selegiline Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline transdermal system (7.8 mg/24 hr)
Study: 9089426
Drug: Baseline (drug-free)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline (drug-free) response to tyramine
Study: 7824763
Drug: Adinazolam 30
Normalized name: adinazolam
DrugBank: Adinazolam (DB00546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adinazolam 30 mg/day
Study: 7824763
Drug: Adinazolam 60
Normalized name: adinazolam
DrugBank: Adinazolam (DB00546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adinazolam 60 mg/day
Study: 7824763
Drug: Adinazolam 90
Normalized name: adinazolam
DrugBank: Adinazolam (DB00546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adinazolam 90 mg/day
Study: 28589238
Drug: Rifaximin (550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin (550 mg three times daily for 2 weeks, followed by two 2-week repeat courses)
Study: 23142439
Drug: 5mg zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5mg zoledronic acid intravenous infusion
Study: 18645274
Drug: Modified-release doxazosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-release doxazosin 4 mg, once a day in the morning, for 2 years
Study: 18645274
Drug: Bladder catheterization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bladder catheterization without medication